The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis

References

• Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs. ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781–7
   PubMed Web of Science ®Google Scholar
• Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000;43:978–87
   PubMed Web of Science ®Google Scholar
• Ehrich EW, Schnitzer TJ, McIlwain H, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6-week double-blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999;26:2438–47
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000;343:1520–8
   PubMed Web of Science ®Google Scholar
• Laine L, Harper S, Simon T, et al. for the Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;83: 776–83
   Google Scholar
• Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370–7
   PubMed Web of Science ®Google Scholar
• Emery P, Zeidler H, Kvien KT, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106–11
   PubMed Web of Science ®Google Scholar
• Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. J Am Med Assoc 1999;282:1921–8
   PubMed Web of Science ®Google Scholar
• Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201–10
   PubMed Web of Science ®Google Scholar
• Hunt RH, Harper S, Watson DJ, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98:1725–33
   PubMed Web of Science ®Google Scholar
• Gottesdiener K, Schnitzer T, Fisher C, et al. for the Protocol 007 Study Group. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatol (Oxford) 2002;41:1052–61
   Google Scholar
• Matsumoto AK, Melian A, Mandel DR, et al. and the Etoricoxib Rheumatoid Arthritis Study Group. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623–30
   Google Scholar
• Bensen W, Weaver, A Espinoza L, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatol (Oxford) 2002;41:1008–16
   PubMed Web of Science ®Google Scholar
• Kivitz A, Eisen G, Zhao WW, et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002;51:530–7
   PubMed Web of Science ®Google Scholar
• Harris SI, Kuss M, Hubbard RC, Goldstein JL. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 2001;23:1422–8
   PubMed Web of Science ®Google Scholar
• Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. J Am Med Assoc 2000;284(10): 1247–55
   Google Scholar
• Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95(7):1681–90
   PubMed Web of Science ®Google Scholar
• Fisher CA, Curtis SP, Resnick H, et al. Treatment with etoricoxib, a COX-2 selective inhibitor, resulted in clinical improvement in knee and hip osteoarthritis (OA) over 52 weeks. Arthritis Rheum 2001;44\(Suppl. 9):S135
   Google Scholar
• Curtis SP, DeTora LM, Leung AT, Sanchez MM, Connors L, Ng J. Etoricoxib showed rapid onset of efficacy and sustained duration of therapy over the 24-hour dosing interval in patients with osteoarthritis (OA) of the knee or hip. Ann Rheum Dis 2002;61\(Suppl. 1):16
   Google Scholar
• Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002; 18:49–58
   PubMed Web of Science ®Google Scholar
• Zacher J, Feldman D, Gerli R, et al. for the Etoricoxib OA Study Group. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003;19:725–36
   Google Scholar
• Curtis SP, Losada B, Bosi-Ferraz M, et al. Etoricoxib and diclofenac demonstrate similar efficacy in a 174-week randomized study of rheumatoid arthritis patients Arthritis Rheum 2003;48\(Suppl. 9):S124–S125
   Google Scholar
• Collantes E, Curtis SP, Lee KW, et al. for the Etoricoxib Rheumatoid Arthritis Study Group. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Family Practice 2002;3:1–29
   Google Scholar
• Melian A, van der Heijde DM, James MK, et al. Etoricoxib in the treatment of ankylosing spondylitis (AS). Arthritis Rheum 2002;46\(Suppl. 9):S432
   Google Scholar
• Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. J Am Med Assoc 1999;282(20):1929–33
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002;359:1686–9
   Google Scholar
• Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New Engl J Med 2005;352:1092–102 [published at www.nejm.org on February 15, 2005]
   Google Scholar
• Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New Engl J Med 2005;352:1071–80 [published at www.nejm.org on February 15, 2005]
   Google Scholar
• Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New Engl J Med 2005;352:1081–91 [published at www. nejm.org on February 15, 2005]
   Google Scholar
• Federal Drug Administration. Etoricoxib: FDA ACM background document. 2005. Available from: www.fda.gov/ohrms/dockets/ac/05/briefing/2005–4090B2_01_Merck-Etoricoxib.pdf [last accessed 16 March 2005]
   Google Scholar